Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Income | $33.4M | $50.1M | $65.7M | $96.6M | $157.1M | $230.7M | $193.5M | ($470.9M) | ($112.2M) | ($155.0M) | $24.0M | ($9,166.0K) | $57.3M | $78.5M | $155.1M | $177.5M | $219.3M | $251.9M | $180.8M | $156.4M |
Discover the top 20 best undervalued stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Feb 2025.
As of today, Amedisys, Inc.'s last 12-month Operating Income is $180.7M, based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, Amedisys, Inc.'s Operating Income growth was 7.2%. The average annual Operating Income growth rates for Amedisys, Inc. have been (9.6%) over the past three years, 1.0% over the past five years.
Over the last year, Amedisys, Inc.'s Operating Income growth was 7.2%, which is higher than industry growth of 3.8%. It indicates that Amedisys, Inc.'s Operating Income growth is Good.